CONMED Corporation Reports 6.7% Sales Increase but Decline in Profitability for Q3 2025

CONMED Corporation reported its financial results for the third quarter and the first nine months of 2025, revealing a net sales increase of 6.7% to $337.9 million for the three months ended September 30, compared to $316.7 million in the same period of 2024. For the nine months, net sales reached $1.001 billion, up 4.2% from $961.1 million year-over-year. The growth was driven by both orthopedic and general surgery product lines, with orthopedic surgery sales increasing by 5.9% and general surgery sales by 7.3% in the third quarter. However, the company experienced a decline in profitability, with net income falling to $2.9 million, or $0.09 per share, from $49.0 million, or $1.59 per share, in the prior year’s quarter.

The company’s gross profit margin decreased significantly, dropping to 49.2% in the third quarter from 56.5% a year earlier, attributed to increased costs of sales, which rose to $171.8 million from $137.7 million. For the nine-month period, gross profit margins also fell to 53.1% from 55.6%. The decline in margins was influenced by $19.7 million in write-offs related to the cancellation of planned product lines and ongoing supply chain challenges, alongside increased operational costs due to inflation and tariffs.

CONMED's selling and administrative expenses surged to $140.3 million in the third quarter, up from $99.7 million in the same period last year, primarily due to higher compensation costs and consulting fees related to operational optimization. Research and development expenses remained stable at $13.9 million for the quarter. The company also reported a decrease in interest expenses, which fell to $7.6 million from $9.3 million, reflecting lower average borrowings and interest rates.

In terms of operational metrics, CONMED's cash and cash equivalents increased to $38.9 million as of September 30, 2025, compared to $24.5 million at the end of 2024. The company’s total assets rose slightly to $2.322 billion from $2.306 billion, while total liabilities decreased to $1.314 billion from $1.344 billion. The company continues to navigate a challenging macroeconomic environment, including supply chain disruptions and inflationary pressures, and is actively working to improve its operational efficiencies. Looking ahead, CONMED anticipates that these factors will continue to impact its financial performance, but it remains committed to strategic investments and operational improvements to drive future growth.